Abstract
ABSTRACTPurpose:To investigate whether renal modifications occur following treatment with dutasteride or finasteride.Methods:Twenty-four male rats were divided into three groups: control (that received distilled water), dutasteride (0.5 mg/kg/day), and finasteride (5 mg/kg/day) groups. All administrations were given by gavage for 40 consecutive days. After inducing euthanasia, blood was collected for urea and creatinine analyses, and both the kidneys were collected for stereological analyses of kidney morphology.Results:Serum urea and creatinine levels were increased in both the finasteride and the dutasteride groups compared with those in the control group. In addition, kidney weight, kidney volume, cortical volume, glomerular volumetric density, and mean glomerular volume were reduced in both treatment groups. Finally, the number of glomeruli per kidney was reduced by 26.8% in the finasteride group and by 51.6% in the dutasteride group compared with that in the control group.Conclusions:The 5-ARIs finasteride and dutasteride promoted morphological and functional damages in rat kidneys. In addition, rats in the dutasteride group showed more severe renal modifications than those in the finasteride group.
Highlights
Blood was collected for urea and creatinine analyses, and both the kidneys were collected for stereological analyses of kidney morphology
The number of glomeruli per kidney was reduced by 26.8% in the finasteride group and by 51.6% in the dutasteride group compared with that in the control group
Benign prostatic hyperplasia (BPH) is a disease characterized by the enlargement of prostatic epithelial and stromal tissues and reduced urinary flow, resulting in manifestations commonly known as lower urinary tract symptoms (LUTS)[1]
Summary
Benign prostatic hyperplasia (BPH) is a disease characterized by the enlargement of prostatic epithelial and stromal tissues and reduced urinary flow, resulting in manifestations commonly known as lower urinary tract symptoms (LUTS)[1]. The first-line pharmacological treatment for BPH indicated by the European Association of Urology and the American Urological Association comprises 5-alpha reductase inhibitors (5-ARIs)[3,4]. This class of drugs prevents the conversion of testosterone to dihydrotestosterone (DHT), which is the most active androgen[2,5]. As the prostate is an androgen-dependent organ, the reduction of DHT levels is often enough to reduce prostate volume and treat clinical symptoms associated with BPH. 5-ARIs decrease the expression of endothelial growth factor (VEGF) and inhibit angiogenesis in the prostate, which explains decreased bleeding observed following prostatectomies[8,9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
